N1-(3-氯苄基)-n1-甲基-1,2-乙二胺 | 103264-69-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N1-(3-氯苄基)-n1-甲基-1,2-乙二胺
• 中文别名: N1-[(3-氯苯基)甲基]-N1-甲基-1,2-乙二胺
• 英文名称: N-(3-chloro-benzyl)-N-methyl-ethylenediamine
• 英文别名: N-(3-Chlor-benzyl)-N-methyl-aethylendiamin；N1-(3-Chlorobenzyl)-N1-methylethane-1,2-diamine；N'-[(3-chlorophenyl)methyl]-N'-methylethane-1,2-diamine
• CAS: 103264-69-3
• 化学式: C₁₀H₁₅ClN₂
• 分子量: 198.695
• InChiKey: MAAYIXSUCPLPIG-UHFFFAOYSA-N

物化性质

• 沸点：
  259℃
• 密度：
  1.115
• 闪点：
  110℃

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  29.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2921590090

反应信息

• 作为反应物：
  描述：

  3-chloro-1-methylpiperidine 、 N1-(3-氯苄基)-n1-甲基-1,2-乙二胺 在 4-甲基-2-戊醇 作用下， 生成 N-(3-chloro-benzyl)-N-methyl-N'-(1-methyl-pyrrolidin-2-ylmethyl)-ethylenediamine
  参考文献：
  名称：

  Aminolysis and Hydrazinolysis Products of N-Methyl-3-chloropiperidine. Non-mercurial Diuretic Agents

  摘要：

  DOI：

  10.1021/ja01519a057
• 作为产物：
  描述：

  3-氯-N-甲基苄胺 在 四氢呋喃 、 lithium aluminium tetrahydride 、 三乙胺 、 甲苯 作用下， 生成 N1-(3-氯苄基)-n1-甲基-1,2-乙二胺
  参考文献：
  名称：

  Aminolysis and Hydrazinolysis Products of N-Methyl-3-chloropiperidine. Non-mercurial Diuretic Agents

  摘要：

  DOI：

  10.1021/ja01519a057

文献信息

• NOVEL MEANS TO MODULATE NMDA RECEPTOR-MEDIATED TOXICITY
  申请人：FUNDAMENTAL PHARMA GMBH

  公开号：US20210347846A1

  公开（公告）日：2021-11-11

  The present invention relates to the field of neurodegenerative processes and means to provide protection against the same. In particular, the present invention relates to polypeptides, fusion proteins, and other compounds interacting with the N-terminal domain of transient receptor potential melastatin subfamily member 4 (TRPM4), which are capable of interfering with NMDA receptor mediated neurotoxicity. The present invention also relates to nucleic acids encoding the aforementioned polypeptides or fusion proteins, compositions comprising the same and the use of said polypeptides, fusion proteins, and other compounds in methods for treating or preventing a disease of the human or animal body, for example in a method of treating diseases like Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), Huntington's disease (HD) or stroke.
• [EN] NOVEL MEANS TO MODULATE NMDA RECEPTOR-MEDIATED TOXICITY<br/>[FR] NOUVEAUX MOYENS PERMETTANT DE MODULER LA TOXICITÉ INDUITE PAR LE RÉCEPTEUR NMDA
  申请人：FUNDAMENTAL PHARMA GMBH

  公开号：WO2020079244A1

  公开（公告）日：2020-04-23

  The present invention relates to the field of neurodegenerative processes and means to provide protection against the same. In particular, the present invention relates to polypeptides, fusion proteins, and other compounds interacting with the N-terminal domain of transient receptor potential melastatin subfamily member 4 (TRPM4), which are capable of interfering with NMDA receptor mediated neurotoxicity. The present invention also relates to nucleic acids encoding the aforementioned polypeptides or fusion proteins, compositions comprising the same and the use of said polypeptides, fusion proteins, and other compounds in methods for treating or preventing a disease of the human or animal body, for example in a method of treating diseases like Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), Huntington's disease (HD) or stroke.
• Aminolysis and Hydrazinolysis Products of N-Methyl-3-chloropiperidine. Non-mercurial Diuretic Agents
  作者：John H. Biel、Wallace K. Hoya、Helen A. Leiser

  DOI：10.1021/ja01519a057

  日期：1959.5